Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Cannabidivarin · CBDV, GWP42006

Small molecule · developed by Jazz Pharmaceuticals

Phase 2 Most advanced trial (none active)
JAZZ Developer
1 Registered trials

What is Cannabidivarin?

Cannabidivarin (CBDV) is a cannabinoid studied at a dose of 10 mg/kg/day in autism spectrum disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CBDV, GWP42006
Drug type
Small molecule
Therapy area
Psychiatry
Developer
Jazz Pharmaceuticals (JAZZ)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
I198VBV98I

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03202303 Phase 2 Autism Spectrum Disorder Completed JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autism Spectrum Disorder

More from Jazz Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Cannabidivarin

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.